PerkinElmer to Present At 2002 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference

07-Feb-2002

BOSTON, (BUSINESS WIRE) -- PerkinElmer, Inc. today announced that it will present at the 2002 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference at 2:10 p.m. ET on Thursday, February 7, 2002, at the Grand Hyatt Hotel in New York City. Robert F. Friel, senior vice president and chief financial officer of PerkinElmer, will provide an overview of the company and its strategic priorities for the coming year. Following Mr. Friel, Frank Witney, president of PerkinElmer Drug Discovery, will detail the company's position in high growth areas including drug and genetic disease screening, functional genomics and proteomics.

PerkinElmer's presentation (audio only) will be webcast live and available for replay for one week following the conference at www.perkinelmer.com.

Factors Affecting Future Performance

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: our ability to successfully integrate Packard BioScience's operations and employees with ours; our ability to realize anticipated synergies and cost savings from the Packard BioScience transaction; our inability to consummate a disposition of the Fluid Sciences business on favorable terms; a downturn in our customers' markets or in general economic conditions; our failure to introduce new products in a timely manner; economic, political and other risks associated with international sales and operations; difficulties integrating technologies, operations and personnel of recent acquisitions; competition from third parties, including pricing pressure; governmental regulation; and our level of debt and the possible incurrence of additional debt in the future. These and other important factors that may affect our actual results are discussed in detail in the risk factors set forth in Amendment No. 1 to our Registration Statement on Form S-4, filed on August 17, 2001 with the Securities and Exchange Commission, under the captions "Risk Factors -- Risks Relating to the Merger" and "Risk Factors -- Risks Relating to PerkinElmer's Business," which discussion is expressly incorporated by reference in this press release.

https://www.chemeurope.com/en/news/8067/perkinelmer-to-present-at-2002-merrill-lynch-pharmaceutical-biotechnology-medical-device-conference.html